Poliomyelitis vaccine is included in standard childhood vaccinations. Since the year 2000, only IPV has been provided in the United States as a series of four children inoculations, establishing an immunity that, while protective for years, waned over time and is, for the most part, undetectable in adults unless a booster is given. Residents of the United States should get a booster shot before travelling to countries where polio is still widespread.
In earlier years, the rapid pace and volume of inactivated
polio vaccine (IPV) introductions, along with the technical challenges of
scaling up production capacity, resulted in significant supply bottlenecks.
SAGE recommended that governments explore moving to fractional dosages of IPV
at the height of the problem. Bangladesh, Cuba, India, Nepal, and Sri Lanka
have all embraced this technique, which offers protection while lowering the
number of vaccines administered. However, 2018 was the first year in which
there was a sufficient supply of inactivated poliovirus, and practically all
introductions that had been delayed or halted due to supply concerns were
resumed during the year. Despite the fact that supply issues continue to
generate a supply-demand imbalance in the markets, we are seeing improvements.
Various governments have taken steps to raise vaccination awareness in order to avoid the spread of polio among the populace. Publicly funded immunization efforts to deliver vaccination to the underprivileged are projected to create a favorable environment for the Global Inactivated Polio Vaccines Market (IPV) to grow rapidly in the near future. For example, the Ghana Health Service (GHS) initiated a series of polio vaccination/immunization campaigns in September 2019 to prevent the virus from spreading in high-risk areas. The inactivated polio vaccine (IPV) will be used to immunise all infants born between January 2016 and June 2018 in all Ghanaian districts during the immunisation polio vaccination campaign.